Compare Pfizer with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs NOVARTIS - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER NOVARTIS PFIZER/
NOVARTIS
 
P/E (TTM) x 49.5 2,162.5 2.3% View Chart
P/BV x 8.2 28.7 28.7% View Chart
Dividend Yield % 0.4 1.5 27.0%  

Financials

 PFIZER   NOVARTIS
EQUITY SHARE DATA
    PFIZER
Mar-19
NOVARTIS
Mar-19
PFIZER/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs3,840980 391.8%   
Low Rs2,080600 346.6%   
Sales per share (Unadj.) Rs455.0198.7 228.9%  
Earnings per share (Unadj.) Rs93.821.0 447.3%  
Cash flow per share (Unadj.) Rs109.422.3 491.5%  
Dividends per share (Unadj.) Rs22.5010.00 225.0%  
Dividend yield (eoy) %0.81.3 60.1%  
Book value per share (Unadj.) Rs658.2307.5 214.1%  
Shares outstanding (eoy) m45.7524.69 185.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.54.0 163.6%   
Avg P/E ratio x31.637.7 83.8%  
P/CF ratio (eoy) x27.135.5 76.2%  
Price / Book Value ratio x4.52.6 175.0%  
Dividend payout %24.047.7 50.3%   
Avg Mkt Cap Rs m135,42019,508 694.2%   
No. of employees `0002.60.6 452.8%   
Total wages/salary Rs m3,2381,171 276.5%   
Avg. sales/employee Rs Th7,911.48,445.4 93.7%   
Avg. wages/employee Rs Th1,230.92,015.7 61.1%   
Avg. net profit/employee Rs Th1,630.7891.0 183.0%   
INCOME DATA
Net Sales Rs m20,8154,907 424.2%  
Other income Rs m1,674783 213.9%   
Total revenues Rs m22,4895,689 395.3%   
Gross profit Rs m5,712123 4,651.5%  
Depreciation Rs m71432 2,245.0%   
Interest Rs m7316 458.5%   
Profit before tax Rs m6,599858 769.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,309340 679.0%   
Profit after tax Rs m4,291518 828.8%  
Gross profit margin %27.42.5 1,096.5%  
Effective tax rate %35.039.6 88.3%   
Net profit margin %20.610.6 195.4%  
BALANCE SHEET DATA
Current assets Rs m27,1678,055 337.3%   
Current liabilities Rs m8,9171,850 482.0%   
Net working cap to sales %87.7126.4 69.3%  
Current ratio x3.04.4 70.0%  
Inventory Days Days6845 150.6%  
Debtors Days Days3034 88.8%  
Net fixed assets Rs m8,862150 5,915.8%   
Share capital Rs m458123 370.7%   
"Free" reserves Rs m29,6567,469 397.1%   
Net worth Rs m30,1137,592 396.7%   
Long term debt Rs m250-   
Total assets Rs m39,4009,824 401.0%  
Interest coverage x91.554.9 166.6%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.5 105.8%   
Return on assets %11.15.4 203.9%  
Return on equity %14.26.8 208.9%  
Return on capital %22.111.5 192.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42858 743.6%   
Fx outflow Rs m7861,326 59.3%   
Net fx Rs m-358-1,269 28.2%   
CASH FLOW
From Operations Rs m978-1,943 -50.3%  
From Investments Rs m3512,742 12.8%  
From Financial Activity Rs m-1,099-298 368.4%  
Net Cashflow Rs m231501 46.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 75.0 85.2%  
Indian inst/Mut Fund % 7.5 2.0 375.0%  
FIIs % 4.9 1.6 306.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 21.5 110.2%  
Shareholders   85,207 41,647 204.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   GLENMARK PHARMA  FULFORD INDIA  ORCHID PHARMA  DIVIS LABORATORIES  UNICHEM LAB  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 350 Points Higher; Dr Reddy's Lab & Tata Steel Top Gainers(09:30 am)

Asian stock markets rose today amid speculation that interest rates will remain low due to receding inflationary pressure.

Related Views on News

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


May 10, 2021 10:42 AM

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS